arXiv:2512.08029v4 Announce Type: replace
Abstract: Clinical decision-making in oncology requires forecasting how disease evolves under treatment, yet most AI systems remain static predictors that ca...
By Tianxingjian Ding, Yuanhao Zou, Chen Chen, Mubarak Shah, Yu Tian
PerturbRx is a treatment‑conditioned representation learning framework that learns latent transitions induced by drug interventions. It trains a drug‑ and dose‑conditioned transition predictor using control and treated single‑cell populations, then applies this predictor to pretreatment patient profiles to generate response features without needing post‑treatment data. On TCGA and patient‑derived xenograft benchmarks, PerturbRx outperforms other methods, demonstrating the value of perturbation‑pretrained latent transitions for patient‑level drug‑response prediction.
By Yoshitaka Inoue, Minoh Jeong, Alfred Hero, Rui Kuang, Augustin Luna
arXiv:2608.24688v1 Announce Type: new
Abstract: Precision oncology necessitates a longitudinal model of patient state that captures cancer evolution and treatment over time, integrating multimodal ob...
By Eugene Vorontsov, Yi Kan Wang, Alican Bozkurt, Adam Casson, Ludmila Tydlitatova, Michal Zelechowski, Ezra E. W. Cohen, Jyoti D. Patel, Max Banaszak, Caitlin McWilliams, Shane Colley, Kate Sasser, Ryan Fukushima, Eric Lefkofsky, Razik Yousfi, Siqi Liu
arXiv:2608. 14355v1 Announce Type: new Abstract: Spatial transcriptomics (ST) enables the simultaneous profiling of gene expression and tissue morphology, creating an opportunity to learn multimodal representations capturing shared morpho-transcriptomic structure.
By Julian Ostermaier, Swann Ruyter, Reuben Dorent, Daniel Racoceanu
arXiv:2607. 04647v1 Announce Type: cross Abstract: Scalable Bayesian inference for generalized linear mixed models (GLMMs) provides uncertainty-aware analysis of correlated longitudinal data, but existing scalable approaches largely assume low-dimensional tabular predictors and do not directly accommodate high-dimensional modalities such as images and text.
By Yuankang Zhao, Youngsoo Baek, Felipe A. Medeiros, Samuel Berchuck, Matthew M. Engelhard
arXiv:2607. 02768v1 Announce Type: cross Abstract: Pathologic complete response and tumor shrinkage measure whether breast cancer responds to neoadjuvant therapy, but not whether that response was structurally favorable, persistent, or hidden beneath volume loss.
By Dattatreya Kantha, Murray H. Loew